$11.37
9.40%
Nasdaq, Wed, Sep 30 2026.
ISIN
US74039M1018
Symbol
POAI

Predictive Oncology Inc Stock price

$11.37
+1.41 14.16% 1M
+9.90 673.47% 6M
+4.22 59.02% YTD
-2.85 20.04% 1Y
-36.11 76.05% 3Y
-387.63 97.15% 5Y
-12,363.63 99.91% 10Y
+11.22 7,480.00% 20Y
Nasdaq, Closing price Wed, Sep 30 2026
-1.18 9.40%

Is Predictive Oncology Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.

Key metrics

Basic
Market capitalization
-
Enterprise Value
-
Net debt
$10.0k
Cash
$180.0k
Shares outstanding
770.0k
Valuation (TTM | estimate)
P/E
negative
P/S
- | -
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
-4.1%
Return on Equity
6,250.9%
ROCE
13.6%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$730.0k | $9.5m
EBITDA
$-10.2m
EBIT
$-10.4m
Net Income
$-84.3m
Free Cash Flow
$-7.9m
Growth (TTM | estimate)
Revenue
-47.1% | 487.7%
EBITDA
20.7%
EBIT
21.9%
Net Income
-503.7%
Free Cash Flow
38.9%
Margin
Gross
50.3%
EBITDA
-1,402.4%
EBIT
-1,421.4%
Net
-11,581.3%
Free Cash Flow
-1,082.5%
More
EPS
$-116.5
FCF per Share
$-10.2
Short interest
2.3%
Employees
24
Rev per Employee
$70.0k

Predictive Oncology Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Predictive Oncology Inc forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Predictive Oncology Inc forecast:

Hold
50%
Sell
50%

Financial data from Predictive Oncology Inc

Sep '25
+/-
%
0.73 0.73
47% 47%
100%
- Direct Costs 0.36 0.36
54% 54%
49%
0.37 0.37
37% 37%
51%
- Selling and Administrative Expenses 8.37 8.37
11% 11%
1,147%
- Research and Development Expense - -
-
-
-10 -10
21% 21%
-1,399%
- Depreciation and Amortization 0.14 0.14
62% 62%
19%
EBIT (Operating Income) EBIT -10 -10
22% 22%
-1,418%
Net Profit -84 -84
504% 504%
-11,552%

In millions USD.

Don't miss a Thing! We will send you all news about Predictive Oncology Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Predictive Oncology, Inc. engages in the application of artificial intelligence medicine business and provision of cleared STREAMWAY System for automated, direct-to-drain medical fluid disposal and associated products. It operates through the following segments: Domestic, International, and Helomics. The Domestic and International segments focuses on STREAMWAY System product sales. The Helomics segment comprises of clinical testing and contract research. The company was founded by Lawrence W. Gadbaw, Peter L. Morawetz, and Jeffrey K. Drogue on April 23, 2002 and is headquartered in Eagan, MN.

Head office United States
CEO Mr. Vennare
Employees 24
Founded 2002
Website predictive-oncology.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today